Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Buildings (2017 - 2019)

Historic Buildings for Takeda Pharmaceutical (TKPHF) over the last 3 years, with Q1 2019 value amounting to $1.1 billion.

  • Takeda Pharmaceutical's Buildings changed N/A to $1.1 billion in Q1 2019 from the same period last year, while for Mar 2019 it was $1.1 billion, marking a year-over-year change of. This contributed to the annual value of $1.1 billion for FY2019, which is N/A changed from last year.
  • As of Q1 2019, Takeda Pharmaceutical's Buildings stood at $1.1 billion.
  • In the past 5 years, Takeda Pharmaceutical's Buildings registered a high of $2.9 billion during Q4 2018, and its lowest value of $1.1 billion during Q1 2019.
  • In the last 3 years, Takeda Pharmaceutical's Buildings had a median value of $1.9 billion in 2017 and averaged $2.0 billion.
  • Over the last 5 years, Takeda Pharmaceutical's Buildings had its largest YoY gain of 5169.27% in 2018, and its largest YoY loss of 5169.27% in 2018.
  • Takeda Pharmaceutical's Buildings (Quarter) stood at $1.9 billion in 2017, then skyrocketed by 51.69% to $2.9 billion in 2018, then plummeted by 61.19% to $1.1 billion in 2019.
  • Its last three reported values are $1.1 billion in Q1 2019, $2.9 billion for Q4 2018, and $1.9 billion during Q4 2017.